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Outpatient Management 
of Heart Failure in the 
United States, 2006–2008
Better outpatient management of heart failure might improve outcomes and reduce the 
number of rehospitalizations. This study describes recent outpatient heart-failure manage-
ment in the United States.
We analyzed data from the National Ambulatory Medical Care Survey of 2006–2008, 
a multistage random sampling of non-Federal physician offices and hospital outpatient 
departments.
Annually, 1.7% of all outpatient visits were for heart failure (51% females and 77% non-
Hispanic whites; mean age, 73 ± 0.5 yr). Typical comorbidities were hypertension (62%), 
hyperlipidemia (36%), diabetes mellitus (35%), and ischemic heart disease (29%). Body 
weight and blood pressure were recorded in about 80% of visits, and health education 
was given in about 40%. The percentage of patients taking β-blockers was 38%; the per-
centage taking angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 
(ACEI/ARBs) was 32%. Medication usage did not differ significantly by race or sex. In 
multivariate-adjusted logistic regression models, a visit to a cardiologist, hypertension, 
heart failure as a primary reason for the visit, and a visit duration longer than 15 minutes 
were positively associated with ACEI/ARB use; and a visit to a cardiologist, heart failure as 
a primary reason for the visit, the presence of ischemic heart disease, and visit duration 
longer than 15 minutes were positively associated with β-blocker use. Chronic obstructive 
pulmonary disease was negatively associated with β-blocker use. Approximately 1% of 
heart-failure visits resulted in hospitalization.
In outpatient heart-failure management, gaps that might warrant attention include sub-
optimal health education and low usage rates of medications, specifically ACEI/ARBs and 
β-blockers. (Tex Heart Inst J 2014;41(3):253-61)
I n the United States, congestive heart failure (HF) affects 5.7 million individuals. There are 700,000 new diagnoses each year.1,2 Congestive HF is characterized by multiple relapses, with an expected one-year rate of hospital readmission of 
more than 50%, and one-year mortality rates of more than 30%.3,4 Accordingly, it 
remains the most frequent hospital-discharge diagnosis. It poses a substantial eco-
nomic burden on the nation’s healthcare system: more Medicare dollars are spent on 
its diagnosis and treatment than on any other diagnosis (total cost, $39.2 billion 
in 2009).1 In this context, improving the outpatient management of HF has been 
suggested as the cornerstone to prevent frequent hospital readmissions and thus cost.5
 The outpatient treatment of HF patients is multidisciplinary and involves several 
steps that are listed in the American College of Cardiology/American Heart Asso-
ciation (ACC/AHA) management guidelines.6 These steps include initial laboratory 
evaluations; documented measurement of left ventricular (LV) function, body weight, 
and blood pressure (BP) during each visit; evaluation and management of clinical 
signs and symptoms of volume overload; evaluation of activity level; educating patients 
about disease management and health-related behavioral changes; and ensuring that 
patients are treated with evidence-based therapy, including angiotensin-converting en-
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zyme inhibitors/angiotensin receptor blockers (ACEI/
ARBs) and β-blockers. Reducing the risk-factor burden 
to prevent ischemic heart disease (IHD) and diastolic 
dysfunction—both of which may worsen HF—is of 
paramount importance.
 Despite the proven survival benefit of medical thera-
pies such as ACEI/ARBs and β-blockers, mortality rates 
in HF patients remain high.7 Little is known about the 
use of these HF medications among outpatients in the 
U.S. In addition, most literature about HF treatment 
and management focuses on systolic HF, despite an 
equal burden of HF with preserved LV ejection frac-
tion (LVEF).6,7 In this study, we used a national sample 
of outpatient visits in the U.S. to describe some impor-
tant performance measures that are suggested by the 
ACC/AHA guidelines for the outpatient management 
of HF. These factors are body weight and BP measure-
ment during each visit, evaluation of LVEF, education 




We used data from the National Ambulatory Medi-
cal Care Survey (NAMCS) 2006–2008, a multistage 
random sampling of non-Federal physician offices and 
hospital outpatient departments within the 50 United 
States and the District of Columbia. The sampling 
design and data collection procedures have been previ-
ously described.8-10 Data from the 2006, 2007, and 2008 
NAMCSs were combined, and weights were divided 
by 3 to generate yearly national estimates of outpatient 
visits for HF.11
Ascertainment of Heart Failure
Data were collected with use of a standard question-
naire that was consistent for all 3 years. The question-
naire answers in regard to patient visits with HF were 
obtained by the following means: a census field repre-
sentative who used a medical chart (46% of responses), 
office staff (32%), physicians (11%), and others (12%). 
Irrespective of the reason for the visit, the survey asked, 
“Does the patient now have heart failure?” This ques-
tion was not included in the survey before 2006.
Study Characteristics
The variables of interest recorded for this study were 
age, sex, race, body mass index, BP, the chief reason for 
the outpatient visit, the type of healthcare provider, time 
that the physician spent with the patient, and the facil-
ity’s use of electronic medical records (EMR). Some rel-
evant comorbidities recorded in the questionnaire were 
hypertension, hyperlipidemia, diabetes mellitus, IHD, 
chronic obstructive pulmonary disease (COPD), asth-
ma, chronic renal insufficiency (CRI), cancer, and psy-
chological depression. Heart failure as a major reason for 
a visit was defined when the medical billing code ICD-
9CM (428.x) was the answer to any of the 3 questions 
about the 3 major reasons for the visit. Information was 
available on several quality-improvement issues, such as 
whether body weight and BP were measured, whether 
further studies were ordered (chest radiograph, electro-
cardiogram, or echocardiogram), and whether health 
education was imparted during each visit.
 Medications administered in the outpatient depart-
ment were recorded in accordance with the National 
Hospital Ambulatory Medical Care Survey List of Na-
tional Drug Codes directory.12 For medications, we used 
variables RX1V1C1 through RX4V3C4—that is, the 
most detailed (level 3) classification of a maximum of 8 
recorded medications. The medications included in our 
analysis were diuretic agents, β-blockers, ACEIs, ARBs, 
inotropic agents, calcium channel blockers (CCB), and 
antiarrhythmic agents.
 Other variables of interest included healthcare system 
characteristics such as the clinic’s location (geographi-
cally, and in a metropolitan statistical area or not), the 
qualifications of the healthcare provider (MD or DO), 
the primary payer, and the specialization of the health-
care provider (cardiologist or non-cardiologist).
Statistical Analysis
The unit of analysis was the patient visit. The response 
rate by healthcare providers was approximately 60%. 
Weighted analyses were adjusted for response rates. All 
analyses used probability weights to generate estimates 
for U.S. patient-visits per year. We adhered to the stan-
dards previously identified by the National Center for 
Health Statistics for acceptable reliability in survey es-
timates.8-10
 Statistical analyses were performed with use of SAS 
statistical software version 9.2 (SAS Institute, Inc.; 
Cary, NC). Descriptive statistics were estimated by 
means of survey routines in the SAS software to account 
for complex survey design. Specif ically, SAS routines 
“Surveymeans” and “Surveylogistic” were used with 
adoption of clustering variables cstratm and cpsum 
and weight variable to account for multistage sampling 
during variance estimation. In addition, we divided 
weights for each year by 3 to derive average yearly esti-
mates. Last, we divided the weight by number of visits 
within the applicable past year to derive the total num-
ber of HF patients visiting outpatient facilities in the 
U.S. Confidence intervals (CI) for binomial variables 
were calculated by using the relative standard error of 
the estimates (SEE). Multivariate logistic regression 
models were built to identify the factors associated with 
use of ACEI/ARBs or β-blockers during each patient-
visit. All odds ratios (ORs) are presented with 95% CIs. 
All tests were 2-tailed, and P <0.05 was considered sta-
tistically significant.
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Results
During the 3 survey years, of a total of 90,588 patient-
visits, 1,555 (1.7%) involved HF. On weighted analysis, 
949 million clinic visits were made each year in the 
U.S., and an estimated 16 million patient-visits were for 
HF. Based on the number of visits within the applicable 
past year, an estimated (± SD) 4.1 ± 0.3 million visits 
for HF occurred. Table I shows the characteristics of the 
patients with HF. The mean (± SE) age of the patients 
was 73 ± 0.5 years; 51% were female, and 77% were 
non-Hispanic whites. The mean body mass index was 
30 ± 0.25 kg/m2, and the mean BP was 128/72 mmHg.
 The predominant reasons for the patient-visits were 
as follows: a routine visit for a chronic problem (54%), 
a new problem within 3 months of onset (18%), re-
currence of a chronic problem (12%), and shortness of 
breath or dyspnea (9%). According to the healthcare 
provider, HF was coded as the primary reason for the 
visit in 35% of HF-patient visits and in 0.61% of all 
outpatient visits.
Heart-Failure Management Characteristics
In patients with HF, body weight was measured and 
recorded in 81% of visits and BP in 82%. Electrolyte 
studies were ordered in 20% of visits and a complete 
blood count in 10%. Imaging was ordered in 20% of 
clinic visits, including radiographs in 7% and echocar-
diograms in 8% (data available only for 2007–2008). 
Current tobacco use was recorded in 10% of all HF 
patients (149 of 1,555); however, tobacco cessation 
counseling was provided to only 26% of those patients 
(39/149). Health education was given to 41% (Table I). 
Specif ically, appropriate education about diet and nu-
trition was given to 19%; about exercise, to 13%; and 
about stress management, to 2%.
 The median number of medications used was 6 (inter-
quartile range [IQR], 2–8). The use of medications spe-
cific to HF included diuretic agents, 42%; β-blockers, 
38%; ACEI/ARBs, 32% (ACEI, 22%; ARB, 10%); 
inotropic agents, 14%; CCB, 11%; vasodilators, 7%; 
and antiarrhythmic agents, 4% (Table I).
 In Table II, differences in performance measures from 
the results of the earlier NAMCS are compared with 
our results.13,14
Predictors of ACEI/ARB Use
In unadjusted univariate analyses, patients who had HF 
as the primary reason for their visit were more likely 
than other patients to be prescribed ACEI/ARB therapy 
(40% vs 27%; Fig. 1A), as were patients seen by a cardi-
ologist versus those seen by a non-cardiologist (44% vs 
28%; Fig. 1B). Hypertensive patients were more likely 
to be prescribed ACEI/ARB therapy than were normo-
tensive patients (35% vs 26%; Fig. 1C). There were no 
significant differences in ACEI/ARB use with regard to 
IHD (Fig. 1D), sex (Fig. 2A), race (Fig. 2B), diabetes 
mellitus (Fig. 2C), CRI (Fig. 2D), or COPD/asthma 
(Fig. 2E). Upon multivariate logistic regression analysis, 
use of ACEI/ARBs among HF patients was more likely 
TABLE I. Characteristics of Heart-Failure Outpatients in 
the United States, 2006–2008*
 Variable Value
Age, yr 73 ± 0.5
Female 786 (51)
Body mass index, kg/m2 30 ± 0.3
Non-Hispanic white 1,168 (77)
Non-Hispanic black 185 (11)
Hispanic 140 (9)
Asian 43 (2)
Systolic blood pressure, mmHg 128 ± 0.6
Diastolic blood pressure, mmHg 72 ± 0.4
Chief reason for patient’s visit 
   Routine visit for chronic problem 835 (54) 
   New problem (<3-mo onset) 288 (18) 
   Recurrence of chronic problem 196 (12) 
   Shortness of breath 140 (9)
Hypertension 989 (62)
Hyperlipidemia 590 (36)
Diabetes mellitus 509 (35)
Ischemic heart disease 464 (29)
COPD, asthma 339 (22)
Chronic renal insufficiency 143 (10)
Cancer 197 (13)
Psychological depression 180 (12)
Health education given 622 (41) 
   Diet and nutrition 272 (19) 
   Exercise 188 (13) 
   Stress management 42 (2) 
   Tobacco cessation 39 (26)**
Medications 
   Diuretic agents 667 (42) 
   β-blockers 649 (38) 
   ACEI/ARBs 542 (32) 
   Calcium channel blockers 189 (11) 
   Inotropic agents 214 (14) 
   Vasodilators 214 (7) 
   Antiarrhythmic agents 143 (4) 
   Median number of medications 6 (IQR, 2–8)
 
ACEI/ARBs = angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers; COPD = chronic obstructive 
pulmonary disease; IQR = interquartile range 
 
* N=1,555, representing 16.1 million heart-failure patient 
visits per year in the National Ambulatory Medical Care 
Survey, 2006–2008.
**Total smokers, N=149. 
 
Unless otherwise stated, data are presented as mean ± 
SE or as number (total number of patients) and percentage 
(weighted analysis to represent heart-failure patient visits 
across the United States).
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TABLE II. Differences in Some Characteristics between the 2 NAMCS Periods
  NAMCS NAMCS NAMCS 
 Variable 1989–1994,13,14 %* 2006–2008, %* 2006–2008, %
Dietary counseling provided 18 21 19
Blood pressure measured 82 95 82
ACEI use 31 40 32
Calcium channel blocker use 15 15 11
Diuretic use 62 55 42




ACEI = angiotensin-converting enzyme inhibitor; NAMCS = National Ambulatory Medical Care Survey 
 
 *When heart failure was the primary reason for the patient’s visit, as coded in one of the 3 diagnoses for the visit. 
 

















HF primary reason: n=539 (35%)



























































Fig. 1  Use of some medications among heart-failure patients: National Ambulatory Medical Care Survey, 2006–2008. N=1,555; 
weighted n=16 million visits/yr. Graphs show visits based on whether A) heart failure was or was not the primary reason for the visit,  
B) examination was by a cardiologist or non-cardiologist, C) patients did or did not have hypertension, and D) patients did or did not 
have ischemic heart disease. 
 
ACEI/ARB = angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; BB = β-blockers; CCB = calcium channel  
blockers; HF = heart failure; IHD = ischemic heart disease 
 
*P <0.05 was considered statistically significant.
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when they were seen by a cardiologist (OR=1.74; 95% 
CI, 1.26–2.40), when HF was the primary reason for 
the visit (OR=1.78; 95% CI, 1.25–2.53), in the presence 
of hypertension (OR=1.69; 95% CI, 1.28–2.24), and 
when visits lasted longer than 15 minutes (OR=1.39; 
95% CI, 1.07–1.82), independent of age, race, sex, geo-
graphic region, metropolitan area, primary payer, IHD, 
diabetes mellitus, CRI, and COPD/asthma.
Predictors of β-Blocker Use
On univariate analysis, patients seen by a cardiologist 
were more likely to be taking β-blockers than were pa-
tients treated by other physicians (65% vs 30%; Fig. 1B), 
as were patients for whom HF was the primary reason 
for the visit (51% vs 31%; Fig. 1A) and patients with 
IHD (52% vs 33%; Fig. 1D). The rate of β-blocker use 
was higher in nondiabetic patients than in diabetic pa-
tients (40% vs 34%; Fig. 2C). There was no significant 
difference in β-blocker use in regard to hypertension 
(Fig. 1C), sex (Fig. 2A), race (Fig. 2B), or CRI (Fig. 2D). 
The presence of COPD/asthma was associated with 
lower use of β-blockers (29% vs 41%, P=0.003; Fig. 
2E). Upon multivariate analysis, β-blocker use was as-
sociated with patients seen by a cardiologist (OR=3.34; 
95% CI, 2.40–5.64), HF as a primary reason for the 
visit (OR=1.84; 95% CI, 1.40–2.53), visits lasting lon-
Fig. 2  Use of some medications among heart-failure patients: 
National Ambulatory Medical Care Survey, 2006–2008. N=1,555; 
weighted n=16 million visits/yr. Graphs show visits by A) sex, B) 
black patients versus others, C) patients with and without dia-
betes mellitus, D) patients with and without chronic renal insuf-
ficiency, and E) patients with and without chronic obstructive 
pulmonary disease or asthma. 
 
ACEI/ARB = angiotensin-converting enzyme inhibitors/angioten-
sin receptor blockers; BB = β-blockers; CCB = calcium channel 
blockers; COPD = chronic obstructive pulmonary disease;  
CRI = chronic renal insufficiency 
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ger than 15 minutes (OR=1.31; 95% CI, 1.00–1.72), 
and the presence of IHD (OR=1.76; 95% CI, 1.23–
2.52), independent of age, sex, race, geographic region, 
metropolitan area, primary payer, diabetes, CRI, hyper-
tension, and COPD/asthma.
 Figure 1A shows the differences in HF-related medi-
cation prescriptions between cardiologists and non-
cardiologists. In addition, both body weight (90% vs 
79%; P <0.001), and BP (93% vs 78%; P <0.001) were 
measured more often during visits to cardiologists than 
non-cardiologists.
Healthcare System Characteristics
Healthcare system characteristics are summarized in 
Table III. A plurality of HF patient visits took place 
in the southern region of the U.S. (43%). More than 
three quarters of all HF patients (77%) had Medicare, 
Medicaid, or both as their primary payer. Most patients 
were seen by an MD (93%). Approximately half of 
HF patients were seen by a general or family medicine 
practitioner or an internist, and 22% were seen by a 
cardiologist. The median duration of the appointment 
was 15 minutes (IQR, 15–25 min). Electronic medical 
records were fully used in 27% of HF visits and par-
tially used in 14%; however, in 58%, EMRs were not 
used at all. When facilities using and not using EMRs 
were compared, there was no appreciable difference in 
either the measurement of BP and body weight or in 
pharmacologic prescriptions (Table IV). Approximately 
1.04% of HF patient-visits resulted in hospitalization.
Discussion
This study provides a comprehensive account of the re-
cent management of HF patients in U.S. outpatient set-
tings. Our important findings were that, in comparison 
with non-cardiologists, cardiologists had higher rates of 
prescribing anti-HF medications (notably ACEI/ARBs 
and β-blockers) and more frequently measured patients’ 
body weight and BP during clinical visits. By providing 
data on general outpatient settings for all HF patients 
during recent years, we extend the results of the Pin-
nacle15 and Improve HF16 studies, which were limited 
to cardiology practices.
 In addition, even though there might be differences 
in HF definition (that is, dependence in previous sur-
veys on ICD codes only, as compared with our ques-
tionnaire query specifically about the presence of HF), 
the number of outpatient HF visits increased from 6 
million in 199414 (1.1% of all outpatient visits) to 16 
million visits per year in our study (1.7% of all visits).
Non-Pharmacologic Performance Measures
Body weight was not measured in 19% of patient-vis-
its, BP was not measured in 18% of patient-visits, and 
health education was not given in 59% of visits. Dietary 
and nutritional counseling was supplied in 19% of all 
visits. The rates of measuring BP and of supplying di-
etary and nutritional counseling did not change greatly 
from the NAMCS of 1989–1994 (Table II).13 No refer-
ences could be found on body-weight measurements in 
the NAMCS to check for differences. Factors such as 
the busy nature of outpatient practice, lack of complete 
EMR, and lack of economic incentives for providing 
complete records might contribute to the low prevalence 
of reporting these non-pharmacologic measures.15
Pharmacologic Performance Measures
Certain CCBs (nondihydropyridines such as diltiazem 
and verapamil) can worsen HF and increase mortal-
ity rates; conversely, other CCBs are considered to be 
safe.17-22 The use of CCBs declined from 15% in 1994 to 
11% in our analysis (Table II).14 Patients seen by a car-
diologist and those with hypertension were more likely 
to be prescribed CCB therapy (Figs. 1B–C). When HF 
was the primary reason for a visit, the usage rate of di-
uretic agents decreased from 62% in 1994 to 55% in 
our study (Table II).14
 Evidence-based guidelines support the use of ACEI/
ARBs in HF.7 The combined usage rate of ACEI/ARBs 
TABLE III. Healthcare System Characteristics in Out-
patient Settings in the United States, 2006–2008* 
            Variable Value
Region 
   Northeast 291 (19) 
   Midwest 376 (22) 
   South 571 (43) 
   West 317 (17) 
   Non-metropolitan area 255 (17)
Primary payer  
   Medicare 999 (67) 
   Medicaid 163 (10) 
   Private insurance 297 (19)
Physician subspecialty  
   General/family medicine 374 (25) 
   Internal medicine 245 (26) 
   Cardiology 477 (22)
Median time spent with physician, min 15 (IQR, 15–25)
Electronic medical records in practice  
   Complete use 432 (27) 
   Partial use 242 (14) 
   No use 875 (58)
 
IQR = interquartile range 
 
* N=1,555, representing 16.1 million heart-failure patient visits 
per year in the National Ambulatory Medical Care Survey, 
2006–2008.
Unless otherwise stated, data are presented as number (total 
number of patients) and percentage (weighted analysis). Results 
are weighted to represent patient visits across the United 
States. Slight differences in numbers might be due to missing 
information for some variables, or not all categories’ having been 
included for a given variable.
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in 2006–2008 among patients for whom HF was coded 
as the primary reason for their visit increased from 31% 
to 40% (1989–1994); however, the overall usage rate 
among patients with HF was 32% (Table II).14 The use 
of ACEI/ARBs was twice as likely when the patient 
visited a cardiologist rather than a non-cardiologist, 
which perhaps points to one of two conclusions: either 
HF can be optimally managed by specialists, or the pro-
file of patients who visit cardiologists is different from 
that of patients who visit other doctors.23 No signif i-
cant differences in ACEI use were found when HF was 
the primary reason for the visit (39% vs 38%; Table 
II). Upon comparison of current study data with those 
published for 1989–1994 for patient-visits primarily for 
HF, the prescription rate for ACEIs increased among 
non-cardiologists (22% formerly to 38% now), and 
they decreased among cardiologists (46% formerly to 
39% now) (Table II).14 No signif icant differences in 
ACEI use were found when HF was the primary reason 
for the visit (39% vs 38%, Table II). The prescription 
rate for ACEI/ARBs by cardiologists in our study was 
lower (44%) than in previous reports (80%–86%, re-
stricted to patients with reduced LVEF).15,16 This can be 
explained by our study’s inclusion of HF patients with 
preserved LVEF, whereas previous reports included 
patients with reduced LVEF (≤0.40),15 a mean LVEF 
of 0.25,16 and disproportionate numbers of males.16 
Angiotensin-converting enzyme inhibitors and ARBs 
have not shown effectiveness in reducing HF-related 
deaths in patients with HF and preserved LVEF (ap-
proximately half the entire HF population).24,25 A com-
parative analysis (2005–2007) of inpatient admissions 
of HF patients with LVEFs <0.35 yielded an 87% rate 
of ACEI/ARB use upon their discharge from the hospi-
tal.26 However, in our study, the use of ACEI/ARBs was 
not statistically signif icant in HF patients with IHD 
(36% vs 30%; Fig. 1D).
 Contrary to our expectations, we found no signif i-
cant differences in ACEI/ARB use among patients with 
and without CRI (Fig. 2D) or with and without dia-
betes (Fig. 2C). We did not study whether the lower 
use was motivated by the expected presence of HF with 
preserved LVEF in about half of HF patients, or by side 
effects such as hyperkalemia. Several barriers might hin-
der physicians’ prescribing ACEI/ARBs, such as unfa-
miliarity with the drugs, concerns about safety profiles 
(hypotension, worsening renal failure, hyperkalemia, 
and cough), and lack of reimbursement incentives to 
provide preventive care.27-30
 Despite the importance of β-blockers in HF thera-
py,31-34 their usage rate increased only slightly, from 32% 
in 200035 to 38% in our study. These rates are low when 
compared with the β-blocker usage rates of 86% to 
93% in cardiology outpatients with reduced LVEFs.15,16 
Of note, HF patients with IHD were 1.6 times more 
likely to have been prescribed this therapy.
 It is widely accepted that HF education and man-
agement by mid-level providers is essential for the op-
timization and maintenance of recommended medical 
therapies and lifestyle interventions that might save tre-
mendous amounts of resources.7,36-40 Because so many 
HF patients are treated by non-cardiovascular experts, 
educating non-cardiologists to maximize the treatment 
of HF patients might improve patients’ adherence to 
TABLE IV. Comparison of Quality-of-Care Variables in Patient Visits with and without the Use of Electronic Medical 
Records
 Variable With EMR (n=680) Without EMR (n=875)
Non-pharmacologic measures
   Blood pressure measured 572 (82) 724 (81)
   Weight taken 556 (84) 684 (80)
Pharmacologic measures (medications used)
   Diuretic agents 290 (47) 378 (39)
   β-blockers 287 (40) 360 (36)
   ACEI/ARBs 243 (32) 297 (31)
   Calcium channel blockers 75 (9) 115 (13)
   Inotropic agents 100 (17) 114 (13)
   Vasodilators 62 (11) 44 (4)
   Antiarrhythmic agents 71 (11) 71 (10)
 
ACEI/ARBs = angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; EMR = electronic medical records 
 
Data are presented as number and percentage.
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interventions and therapeutic regimens. Wider dissemi-
nation of the current HF-management guidelines in 
formats to suit the busy schedule of healthcare providers 
might be useful.
Strengths and Limitations of the Study
Whereas previous studies could comment only on pa-
tients whose chief reason for a doctor visit was HF, our 
inclusion of a mandatory survey question about conges-
tive HF as a comorbidity enabled more generalization. 
No HF diagnosis was verified independently, although 
previous reports indicate very high positive predictive 
value for that diagnosis in hospital administrative da-
tabases (~95%).41,42
 Several limitations warrant mention. The unit of 
analysis was a patient-visit rather than a patient. It is 
plausible that a single patient made more than one visit. 
We were able to estimate numbers of patients by ac-
counting for the number of visits that each patient made 
during the last year. In addition, it was noteworthy 
that data were collected from visits during one-week pe-
riods and were given very low sampling probability for 
each visit; the chances of re-sampling a patient during 
and across survey years were minimal. Data were insuf-
f icient to characterize HF type (systolic vs diastolic), 
HF symptoms and their duration, New York Heart As-
sociation functional status, physical examination find-
ings, laboratory results such as basic metabolic panel, 
biomarkers such as pro-brain natriuretic peptide, and 
diagnostic testing such as echocardiography. Data on 
the optimal doses, contraindications, and adverse ef-
fects of ACEI, ARB, and β-blockers were also sparse. 
Data on medication compliance were unavailable. Of 
importance, medication use might have been underre-
ported, because the permissible number of medications 
to record was 8. Generalization to care by physicians 
who practice in publicly funded clinics cannot be made, 
because of their exclusion from the NAMCS database.
 In conclusion, we found an underuse of both phar-
macologic and non-pharmacologic measures. Patients’ 
having been seen by cardiologists, and longer time spent 
during visits, were strong predictors of higher usage 
rates of β-blockers and ACEI/ARBs.
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